Zuranolone治疗成人重度抑郁症:随机安慰剂对照3期试验
该随机双盲安慰剂对照3期试验纳入18-64岁重度抑郁症患者,每日一次口服zuranolone 50 mg或安慰剂共14天。第15天zuranolone组HAM-D总分较基线改善显著优于安慰剂组(-14.1 vs. -12.3),第3天即见数值上更大改善并持续至随访期。安全性与既往较低剂量研究一致。
要点
- zuranolone 50 mg每日一次治疗14天,第15天HAM-D改善显著优于安慰剂。
- 第3天即观察到数值上更大的症状改善,并持续至研究随访期。
- 安全性与既往较低剂量研究相比未见新发现,两组严重不良事件各2例。
核心结论
- zuranolone 50 mg/日治疗14天在第15天显著改善重度抑郁症患者抑郁症状,起效迅速(第3天)。
- zuranolone总体耐受良好,与既往研究的较低剂量相比无新安全性发现。
研究设计与样本
- 随机、双盲、安慰剂对照3期试验,纳入18-64岁重度抑郁症患者。
- 患者每日一次自行服用zuranolone 50 mg或安慰剂,共14天。
- 543例随机化患者中534例构成全分析集(zuranolone组266例,安慰剂组268例)。
主要发现
- 第15天HAM-D总分较基线最小二乘均值变化:zuranolone组-14.1,安慰剂组-12.3,差异有统计学意义。
- 第3天HAM-D总分较基线最小二乘均值变化:zuranolone组-9.8,安慰剂组-6.8,数值上zuranolone更优。
- 改善持续至研究治疗和随访期所有访视(至第42天),差异至第12天保持名义显著。
- 两组各有2例患者发生严重不良事件;因不良事件停药者zuranolone组9例,安慰剂组4例。
临床怎么用
- 对于重度抑郁症成人患者,可考虑zuranolone 50 mg每日一次14天方案,但需结合当地获批情况与患者个体评估。
- 治疗早期(第3天)即可评估症状改善趋势,并关注不良事件及停药风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study assessed the efficacy and safety of a 14-day treatment course of once-daily zuranolone 50 mg, an investigational oral positive allosteric modulator of the γ-aminobutyric acid type A (GABAA) receptor, for the treatment of major depressive disorder. METHODS: Patients 18-64 years of age with severe major depressive disorder were enrolled in this randomized, double-blind, placebo-controlled trial. Patients self-administered zuranolone 50 mg or placebo once daily for 14 days. The primary endpoint was change from baseline in total score on the 17-item Hamilton Depression Rating Scale (HAM-D) at day 15. Safety and tolerability were assessed by incidence of adverse events. RESULTS: Of 543 randomized patients, 534 (266 in the zuranolone group, 268 in the placebo group) constituted the full analysis set. Compared with patients in the placebo group, patients in the zuranolone group demonstrated a statistically significant improvement in depressive symptoms at day 15 (least squares mean change from baseline HAM-D score, -14.1 vs. -12.3). Numerically greater improvements in depressive symptoms for zuranolone versus placebo were observed by day 3 (least squares mean change from baseline HAM-D score, -9.8 vs. -6.8), which were sustained at all visits throughout the treatment and follow-up periods of the study (through day 42, with the difference remaining nominally significant through day 12). Two patients in each group experienced a serious adverse event; nine patients in the zuranolone group and four in the placebo group discontinued treatment due to adverse events. CONCLUSIONS: Zuranolone at 50 mg/day elicited a significantly greater improvement in depressive symptoms at day 15, with a rapid time to effect (day 3). Zuranolone was generally well tolerated, with no new safety findings compared with previously studied lower dosages. These findings support the potential of zuranolone in treating adults with major depressive disorder.
引用
- Clayton AH, Lasser R, Parikh SV, et al. Zuranolone for the Treatment of Adults With Major Depressive Disorder: A Randomized, Placebo-Controlled Phase 3 Trial. Am J Psychiatry. 2023. PMID: 37132201. doi:10.1176/appi.ajp.20220459
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。